Ian Kloer’s Strategy for Darya-Varia Laboratoria’s Next Half-Century

Kloer, a former medical doctor with two decades of commercial experience, arrived with a mandate to stabilize the firm while preparing for post-pandemic growth. His approach defied the industry trend of cost-cutting; he instead accelerated investments in digital communication and hybrid engagement programs. This calculated risk allowed the company to maintain supply chains and support healthcare workers when competitors were pulling back resources. The strategy proved successful, shifting the company’s focus from traditional manufacturing toward a broader, integrated healthcare model.

To facilitate this evolution, the company launched a subsidiary, Varia Interhealth Indonesia, aimed at diversifying the portfolio and balancing market risks. Kloer credits this progress to a culture of open communication with long-term partners like Pura Group and Nitta Gelatin, some of whom have maintained ties with the firm for over three decades. As the company marks its 50th anniversary in Indonesia, the leadership team is prioritizing operational excellence alongside innovation. Kloer views the workforce, whom he affectionately calls DVL warriors, as the primary engine for this ongoing transformation, ensuring that the company remains competitive while addressing the evolving healthcare needs of the population.